Research Summary

Dr. Boyle is a translational scientist with research interests that include pediatric cancer therapeutics, pharmacokinetics, pharmacodynamics, pharmacogenomics, and clinical trial design. The majority of her research resides within the complex setting of hematopoietic cell transplantation (HCT) and is focused around chemotherapeutic and immunosuppressive agents used in the preparative regimens of pediatric HCT. Specifically, Dr. Boyle studies how covariates such as age, renal function, or genetic variants involved in drug metabolism or distribution may influence drug clearance in the pediatric HCT population.

Education

University of Minnesota, Minneapolis, BS, 2000, Biochemistry
University of Minnesota, Minneapolis, PharmD, 2006, Pharmacy
University of Minnesota, Minneapolis, PhD, 2009, Experimental and Clinical Pharmacology

Honors & Awards

  • 2010
    Early Career Research Award, Thrasher Pediatric Research Fund
  • 2011
    Travel Award for Early Career Researchers, UCSF Academic Senate
  • 2011
    Loan Repayment Recipient (2-year contract), National Institutes of Health Pediatric LRP
  • 2012
    Gary Rifkind Research Award for Junior Faculty, UCSF School of Pharmacy
  • 2013
    Loan Repayment Recipient (renewal, 2-year contract), National Institutes of Health Pediatric LRP
  • 2017
    Mid-Career Level Travel Award, UCSF Academic Senate

Selected Publications

  1. Dvorak CC, Temple WC, Cisneros GS, Chu J, Winestone LE, Higham CS, Shimano KA, Kharbanda S, Avagyan S, Pauerstein P, Huang JN, Cheng G, Waters E, Winger BA, Cowan MJ, Long-Boyle JR. Younger children with nonmalignant disease have increased incidence of mixed myeloid chimerism after allogeneic hematopoietic cell transplantation with busulfan-based conditioning. Transplant Cell Ther. 2025 Apr; 31(4):259.e1-259.e15.  View on PubMed
  2. Dvorak CC, Long-Boyle JR, Holbrook-Brown L, Abdel-Azim H, Bertaina A, Vatsayan A, Talano JA, Bunin N, Anderson E, Flower A, Lalefar N, Higham CS, Kapoor N, Klein O, Odinakachukwu MC, Cho S, Jacobsohn DA, Collier W, Pulsipher MA. Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19-depleted pediatric haploidentical HCT for hematologic malignancy. Blood Adv. 2024 Dec 10; 8(23):6003-6014.  View on PubMed
  3. Mike JK, White Y, Ha J, Iranmahboub A, Hawkins C, Hutchings RS, Vento C, Manzoor H, Wang A, Goudy BD, Vali P, Lakshminrusimha S, Gobburu JVS, Long-Boyle J, Fineman JR, Ferriero DM, Maltepe E. Perinatal Caffeine Administration Improves Outcomes in an Ovine Model of Neonatal Hypoxia-Ischemia. Stroke. 2024 Nov; 55(11):2705-2715.  View on PubMed
  4. Bognàr T, Garcia-Rosa M, Lalmohamed A, Güngör T, Hauri-Hohl M, Prockop S, Oram L, Pai SY, Brooks J, Savic RM, Dvorak CC, Long-Boyle JR, Krajinovic M, Bittencourt H, Teyssier AC, Théorêt Y, Martinez C, Egberts TCG, Morales E, Slatter M, Cuvelier GDE, Chiesa R, Wynn RF, Coussons M, Cicalese MP, Ansari M, Long SE, Ebens CL, Lust H, Chaudhury S, Nath CE, Shaw PJ, Keogh SJ, van der Stoep MYEC, Bredius R, Lindemans CA, Boelens JJ, Bartelink IH. Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity. Blood Adv. 2024 10 08; 8(19):5137-5145.  View on PubMed
  5. Jung D, Long-Boyle JR, Pang WW, Gobburu JVS. Pharmacokinetics of Briquilimab as a Conditioning Agent for Hematopoietic Stem Cell Transplantation in Patients With Severe Combined Immunodeficiency, Myelodysplastic Syndrome, or Acute Myeloid Leukemia. Transplant Cell Ther. 2024 Sep; 30(9):923.e1-923.e9.  View on PubMed
  6. Higham CS, Shimano KA, Kharbanda S, Chu J, Cisneros GS, Winestone LE, Dara J, Huang JN, Hermiston ML, Long-Boyle JR, Dvorak CC. Cyclophosphamide and Thiotepa Increases Risk of Transplant-Associated Thrombotic Microangiopathy. Transplant Cell Ther. 2024 Sep; 30(9):931.e1-931.e10.  View on PubMed
  7. Salinas Cisneros G, Dvorak CC, Long-Boyle J, Kharbanda S, Shimano KA, Melton A, Chu J, Winestone LE, Dara J, Huang JN, Hermiston ML, Zinter M, Higham CS. Diagnosing and Grading of Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplant of Children, Adolescent and Young Adults treated in a Pediatric Institution with Pediatric Protocols. Transplant Cell Ther. 2024 Jul; 30(7):690.e1-690.e16.  View on PubMed
  8. Hughes JH, Long-Boyle J, Keizer RJ. Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing. J Pharmacokinet Pharmacodyn. 2024 Jun; 51(3):279-288.  View on PubMed
  9. Mike JK, White Y, Hutchings RS, Vento C, Ha J, Iranmahboub A, Manzoor H, Gunewardena A, Cheah C, Wang A, Goudy BD, Lakshminrusimha S, Long-Boyle J, Fineman JR, Ferriero DM, Maltepe E. Effect of Clemastine on Neurophysiological Outcomes in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy. Children (Basel). 2023 Oct 25; 10(11).  View on PubMed
  10. Long-Boyle JR, Kohn DB, Shah AJ, Spencer SM, Sevilla J, Booth C, López Lorenzo JL, Nicoletti E, Shah A, Reatz M, Matos J, Schwartz JD. Busulfan and subsequent malignancy: An evidence-based risk assessment. Pediatr Blood Cancer. 2024 Jan; 71(1):e30738.  View on PubMed
  11. Mike JK, White Y, Hutchings RS, Vento C, Ha J, Manzoor H, Lee D, Losser C, Arellano K, Vanhatalo O, Seifert E, Gunewardena A, Wen B, Wang L, Wang A, Goudy BD, Vali P, Lakshminrusimha S, Gobburu JVS, Long-Boyle J, Wu YW, Fineman JR, Ferriero DM, Maltepe E. Perinatal Azithromycin Provides Limited Neuroprotection in an Ovine Model of Neonatal Hypoxic-Ischemic Encephalopathy. Stroke. 2023 11; 54(11):2864-2874.  View on PubMed
  12. Cowan MJ, Yu J, Facchino J, Fraser-Browne C, Sanford U, Kawahara M, Dara J, Long-Boyle J, Oh J, Chan W, Chag S, Broderick L, Chellapandian D, Decaluwe H, Golski C, Hu D, Kuo CY, Miller HK, Petrovic A, Currier R, Hilton JF, Punwani D, Dvorak CC, Malech HL, McIvor RS, Puck JM. Lentiviral Gene Therapy for Artemis-Deficient SCID. N Engl J Med. 2022 12 22; 387(25):2344-2355.  View on PubMed
  13. Brooks JT, Solans BP, Lu Y, Kharbanda S, Dvorak CC, Lalefar N, Long S, Gupta AO, Horn B, Lamba JK, Huang L, Apsel-Winger B, Keizer RJ, Savic R, Long-Boyle J. Prospective Validation and Refinement of a Population Pharmacokinetic Model of Fludarabine in Children and Young Adults Undergoing Hematopoietic Cell Transplantation. Pharmaceutics. 2022 Nov 15; 14(11).  View on PubMed
  14. Huang L, Winger BA, Cheah V, Gingrich D, Marzan F, Lu Y, Cooper JC, Aweeka F, Long-Boyle J. Quantification of N, N' N"-triethylenethiophosphoramide, N, N"-triethylenephosphoramide, cyclophosphamide, and 4-hydroxy-cyclophosphamide in microvolume human plasma to support neonatal and pediatric drug studies. J Chromatogr Open. 2022 Nov; 2.  View on PubMed
  15. Mike JK, Wu KY, White Y, Pathipati P, Ndjamen B, Hutchings RS, Losser C, Vento C, Arellano K, Vanhatalo O, Ostrin S, Windsor C, Ha J, Alhassen Z, Goudy BD, Vali P, Lakshminrusimha S, Gobburu JVS, Long-Boyle J, Chen P, Wu YW, Fineman JR, Ferriero DM, Maltepe E. Defining Longer-Term Outcomes in an Ovine Model of Moderate Perinatal Hypoxia-Ischemia. Dev Neurosci. 2022; 44(4-5):277-294.  View on PubMed
  16. Li S, Dvorak CC, Lu Y, Chan D, Gobburu JVS, Long-Boyle J, Apsel Winger B. Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation. J Clin Pharmacol. 2022 07; 62(7):873-882.  View on PubMed
  17. Bognàr T, Bartelink IH, Egberts TCG, Rademaker CMA, Versluys AB, Slatter MA, Kletzel M, Nath CE, Cuvelier GDE, Savic RM, Dvorak C, Long-Boyle JR, Cowan MJ, Bittencourt H, Bredius RGM, Güngör T, Shaw PJ, Ansari M, Hassan M, Krajinovic M, Hempel G, Marktel S, Chiesa R, Théoret Y, Lund T, Orchard PJ, Wynn RF, Boelens JJ, Lalmohamed A. Association Between the Magnitude of Intravenous Busulfan Exposure and Development of Hepatic Veno-Occlusive Disease in Children and Young Adults Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 04; 28(4):196-202.  View on PubMed
  18. Brooks JT, Keizer RJ, Long-Boyle JR, Kharbanda S, Dvorak CC, Friend BD. Population Pharmacokinetic Model Development of Tacrolimus in Pediatric and Young Adult Patients Undergoing Hematopoietic Cell Transplantation. Front Pharmacol. 2021; 12:750672.  View on PubMed
  19. Takahashi T, Illamola SM, Jennissen CA, Long SE, Lund TC, Orchard PJ, Gupta AO, Long-Boyle JR. Busulfan dose Recommendation in Inherited Metabolic Disorders: Population Pharmacokinetic Analysis. Transplant Cell Ther. 2022 02; 28(2):104.e1-104.e7.  View on PubMed
  20. Bankova AK, Pang WW, Velasco BJ, Long-Boyle JR, Shizuru JA. 5-Azacytidine depletes HSCs and synergizes with an anti-CD117 antibody to augment donor engraftment in immunocompetent mice. Blood Adv. 2021 10 12; 5(19):3900-3912.  View on PubMed

Go to UCSF Profiles, powered by CTSI